IFN‐γ Driven Hepatic Injury Exacerbates Mortality in NK/T‐Cell Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis
Cancer Medicine · 2026
DOI: 10.1002/cam4.71606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yehua Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Interferon-gamma, Lymphoma, Extranodal NK-T-Cell, Liver Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ninth People's Hospital, Shanghai Jiao-Tong University School of Medicine, Clinical Research Program of 9th People's Hospital affiliated to Shanghai Jiao-Tong University School of Medicine.
Abstract (Originalsprache)
Background
Hepatic involvement is a life‐threatening complication in natural killer/T‐cell lymphoma with hemophagocytic lymphohistiocytosis (NK/T‐HLH). Nevertheless, the prognostic implications of hepatic dysfunction and its underlying related factors are not fully elucidated.
Methods
We retrospectively analyzed the clinical and laboratory data of 53 NK/T patients, comprising 35 cases without HLH and 18 with HLH. All NK/T‐HLH patients exhibited hepatic injury, characterized by significantly elevated hepatic enzyme levels and bilirubin compared to those without HLH (all p < 0.001). Glutamyltransferase (GGT), aspartate aminotransferase (AST), and direct bilirubin (DBIL) individually predicted mortality with AUC > 0.8 in NKTCL patients, while their composite GSD index enhanced predictive accuracy (AUC = 0.87).
Results
Notably, NK/T‐HLH patients meeting the GSD index criteria had markedly reduced overall survival (OS) compared to non‐fulfillers (median OS: 2 vs 21 months; p = 0.003). Patients with hepatic involvement exhibited significantly higher levels of serum interferon‐γ(IFN‐γ) and interleukin‐10 (IL‐10). While, only IFN‐γ concentrations showed a strong positive correlation with the elevated levels of GGT, AST, and DBIL. To further validate the clinical relevance of these findings, we present two representative cases of NK/T‐HLH with severe hepatic injury. Both patients achieved rapid liver function recovery following a targeted regimen combining chemotherapy and emapalumab, a human anti‐IFN‐γ monoclonal antibody approved for primary HLH.
Conclusion
The GSD index emerges as a robust prognostic tool for NK/T‐HLH patients with hepatic dysfunction, reflecting underlying IFN‐γ‐mediated immunopathology. Early intervention with anti‐IFN‐γ monoclonal antibody may improve clinical outcomes in this high‐risk subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, China.
ORCID-Profile: Yehua Yu, Liyuan Ma, Yuyang Pang
Förderung
- Ninth People's Hospital, Shanghai Jiao-Tong University School of Medicine
- Clinical Research Program of 9th People's Hospital affiliated to Shanghai Jiao-Tong University School of Medicine
Zitieren
APA
Yu, Y., Ma, L., Hang, H., Pang, Y., Lu, W., Liu, J., Zhou, H., & Shi, J. (2026). IFN‐γ Driven Hepatic Injury Exacerbates Mortality in NK/T‐Cell Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis. Cancer Medicine. https://doi.org/10.1002/cam4.71606
Vancouver
Yu Y, Ma L, Hang H, Pang Y, Lu W, Liu J, et al. IFN‐γ Driven Hepatic Injury Exacerbates Mortality in NK/T‐Cell Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis. Cancer Medicine. 2026. doi:10.1002/cam4.71606
BibTeX
@article{Yu2026,
author = {Yu, Yehua and Ma, Liyuan and Hang, Haifang and Pang, Yuyang and Lu, Wei and Liu, Jiajia and Zhou, Hui and Shi, Jun},
title = {IFN‐γ Driven Hepatic Injury Exacerbates Mortality in NK/T‐Cell Lymphoma‐Associated Hemophagocytic Lymphohistiocytosis},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71606}
}
EUVIMED